Provided by Tiger Trade Technology Pte. Ltd.

Teva Pharmaceutical

41.10
+1.854.71%
Post-market: 41.210.1100+0.27%19:59 EDT
Volume:14.82M
Turnover:610.54M
Market Cap:47.88B
PE:68.50
High:42.02
Open:40.22
Low:40.12
Close:39.25
52wk High:42.02
52wk Low:18.83
Shares:1.17B
Float Shares:1.09B
Volume Ratio:3.10
T/O Rate:1.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.6000
EPS(LYR):1.21
ROE:9.69%
ROA:5.13%
PB:6.18
PE(LYR):33.97

Loading ...

Truist Raises Price Target on Teva Pharmaceutical Industries to $45 From $42, Keeps Buy Rating

MT Newswires Live
·
Apr 30

Piper Sandler Reaffirms Their Buy Rating on Teva Pharmaceutical (TEVA)

TIPRANKS
·
Apr 30

A Look At Teva (TEVA) Valuation After Strong Q1 2026 Earnings And Biosimilar Pipeline Progress

Simply Wall St.
·
Apr 30

Teva Upgraded to $45 Price Target on Strong Execution, Emalex Acquisition, and Growing Neurology Pipeline Upside

TIPRANKS
·
Apr 30

Teva price target raised to $45 from $42 at Truist

TIPRANKS
·
Apr 30

Stock Track | Teva Pharmaceutical Soars 12.02% Intraday on Strong Q1 Earnings Beat and Emalex Acquisition

Stock Track
·
Apr 29

Sector Update: Health Care

MT Newswires Live
·
Apr 29

Teva Pharmaceuticals Exec Says Co's Operations Remain Uninterrupted With No Material Impact on 2026 Guidance - Conf Call

THOMSON REUTERS
·
Apr 29

Teva Pharmaceuticals Exec Says It Is Difficult to Predict Whether There Will Be a Channel Drawdown Ahead of Price Changes Set to Take Effect in 2027

THOMSON REUTERS
·
Apr 29

Teva Pharmaceuticals Exec Says Co Is Seeing Nominal Increases in Some Transportation and Energy Costs Related to Middle East Conflict

THOMSON REUTERS
·
Apr 29

Teva Pharmaceuticals Exec Says Co Continue to Monitor Geopolitical Situation in the Middle East - Conf Call

THOMSON REUTERS
·
Apr 29

Teva reports Q1 EPS 53c, consensus 46c

TIPRANKS
·
Apr 29

Teva Pharmaceutical Beats First-Quarter Profit Estimates On Branded Drugs Demand

Reuters
·
Apr 29

GUIDANCE: (TEVA) Teva Pharmaceutical Industries Expects 2026 Non-GAAP EPS Range $1.91 - 2.11

MT Newswires Live
·
Apr 29

Stock Track | Teva Pharmaceutical Soars 5.41% in Pre-Market on Strong Q1 Earnings Beat and Emalex Acquisition

Stock Track
·
Apr 29

Teva Pharmaceutical Indus Q1 Adj. EPS $0.53 Beats $0.48 Estimate, Sales $3.982B Beat $3.810B Estimate

Benzinga Earnings
·
Apr 29

Press Release: Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution

Dow Jones
·
Apr 29

Teva to acquire Emalex Biosciences for $700M at closing

TIPRANKS
·
Apr 29

Notable companies reporting before tomorrow’s open

TIPRANKS
·
Apr 29

Teva put volume heavy and directionally bearish

TIPRANKS
·
Apr 29